Methotrexate-F127 conjugated mesoporous zinc hydroxyapatite as an efficient drug delivery system for overcoming chemotherapy resistance in osteosarcoma cells

被引:59
作者
Meshkini, Azadeh [1 ]
Oveisi, Harnid [2 ]
机构
[1] Ferdowsi Univ Mashhad, Dept Chem, Fac Sci, Mashhad 9177948974, Iran
[2] Hakim Sabzevari Univ, Dept Mat & Polymer Engn, Sabzevar 9617976487, Iran
关键词
Mesoporous hydroxyapatite; Methotrexate; F127; Resistance osteosarcoma cell; SUBSTITUTED HYDROXYAPATITES; BIOMEDICAL APPLICATIONS; CALCIUM PHOSPHATES; CONTROLLED-RELEASE; ANTICANCER DRUG; P-GLYCOPROTEIN; NANOPARTICLES; FOLATE; ENDOCYTOSIS; PATHWAY;
D O I
10.1016/j.colsurfb.2017.07.006
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The resistance of cancer cells to chemotherapeutic agents and the poor selectivity of drugs toward tumor cells are regarded as the main impediments in successful cancer therapy. Currently, the design and fabrication of stimulus-responsive drug delivery systems with high specificity toward cancer cells are gaining increasing attention and they show a promising potential for clinical applications. In this study, mesoporous zinc-substituted hydroxyapatite has been synthesized and served as a drug delivery vehicle owing to its biocompatibility and high drug loading capacity. The mesoporous nanoparticles were decorated with F127 and subsequently conjugated with methotrexate (MTX) through a stable amide linkage. Since folate receptors are overexpressed on many tumor cell surfaces, MTX on the nanocarrier system plays a dual role as a targeting molecule and a chemotherapeutic drug. The evaluation of the drug release profile revealed that MTX was cleaved from the nanoparticles by a certain type of enzyme under low pH conditions that are meant to simulate the intracellular conditions in the lysosome. Cell viability studies on primary osteosarcoma cells (Saos-2) and MTX-resistance cell lines (RSaos-2/MTX) revealed that the drug-loaded nanoparticles possess high antitumor efficacy on both of the cell lines relative to free MTX. It was also found that the inhibition of P-glycoproteins by F127 and the release of Zn2+ ions from the nanoparticles in an acidic environment effectively potentiate the antitumor efficacy of the drug-loaded nanoparticles, leading to caspase-mediated cell death. Based on these data, MTX-F127@ZnHAP nanoparticles are pH-responsive nanocarriers with precise controlled drug release and targeting effect. Therefore, they are considered to be promising candidates capable of overcoming resistance in osteosarcoma cells. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:319 / 330
页数:12
相关论文
共 43 条
[1]   Recent progress in biomedical applications of Pluronic (PF127): Pharmaceutical perspectives [J].
Akash, Muhammad Sajid Hamid ;
Rehman, Kanwal .
JOURNAL OF CONTROLLED RELEASE, 2015, 209 :120-138
[2]   The Redox State of Cytochrome C Modulates Resistance to Methotrexate in Human MCF7 Breast Cancer Cells [J].
Barros, Susana ;
Mencia, Nuria ;
Rodriguez, Laura ;
Oleaga, Carlota ;
Santos, Conceicao ;
Noe, Veronique ;
Ciudad, Carlos J. .
PLOS ONE, 2013, 8 (05)
[3]   Functions of zinc in signaling, proliferation and differentiation of mammalian cells [J].
Beyersmann, D ;
Haase, H .
BIOMETALS, 2001, 14 (3-4) :331-341
[4]   INHIBITING EFFECT OF ZINC ON HYDROXYLAPATITE CRYSTALLIZATION [J].
BIGI, A ;
FORESTI, E ;
GANDOLFI, M ;
GAZZANO, M ;
ROVERI, N .
JOURNAL OF INORGANIC BIOCHEMISTRY, 1995, 58 (01) :49-58
[5]   Calcium phosphate ceramic systems in growth factor and drug delivery for bone tissue engineering: A review [J].
Bose, Susmita ;
Tarafder, Solaiman .
ACTA BIOMATERIALIA, 2012, 8 (04) :1401-1421
[6]   Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide [J].
Chen, Haimei ;
Ahn, Richard ;
Van den Bossche, Jeroen ;
Thompson, David H. ;
O'Halloran, Thomas V. .
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (07) :1955-1963
[7]   Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialaEuro [J].
Clement, P. M. ;
Gauler, T. ;
Machiels, J. P. ;
Haddad, R. I. ;
Fayette, J. ;
Licitra, L. F. ;
Tahara, M. ;
Cohen, E. E. W. ;
Cupissol, D. ;
Grau, J. J. ;
Guigay, J. ;
Caponigro, F. ;
de Castro, G., Jr. ;
de Souza Viana, L. ;
Keilholz, U. ;
del Campo, J. M. ;
Cong, X. J. ;
Ehrnrooth, E. ;
Vermorken, J. B. .
ANNALS OF ONCOLOGY, 2016, 27 (08) :1585-1593
[8]   Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 [J].
Colleoni, Marco ;
Gray, Kathryn P. ;
Gelber, Shari ;
Lang, Istvan ;
Thurlimann, Beat ;
Gianni, Lorenzo ;
Abdi, Ehtesham A. ;
Gomez, Henry L. ;
Linderholm, Barbro K. ;
Puglisi, Fabio ;
Tondini, Carlo ;
Kralidis, Elena ;
Eniu, Alexandru ;
Cagossi, Katia ;
Rauch, Daniel ;
Chirgwin, Jacquie ;
Gelber, Richard D. ;
Regan, Meredith M. ;
Coates, Alan S. ;
Price, Karen N. ;
Viale, Giuseppe ;
Goldhirsch, Aron .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) :3400-+
[9]   High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) [J].
Fritsch, K. ;
Kasenda, B. ;
Schorb, E. ;
Hau, P. ;
Bloehdorn, J. ;
Moehle, R. ;
Loew, S. ;
Binder, M. ;
Atta, J. ;
Keller, U. ;
Wolf, H-H ;
Krause, S. W. ;
Hess, G. ;
Naumann, R. ;
Sasse, S. ;
Hirt, C. ;
Lamprecht, M. ;
Martens, U. ;
Morgner, A. ;
Panse, J. ;
Frickhofen, N. ;
Roeth, A. ;
Hader, C. ;
Deckert, M. ;
Fricker, H. ;
Ihorst, G. ;
Finke, J. ;
Illerhaus, G. .
LEUKEMIA, 2017, 31 (04) :846-852
[10]   Development and characterization of single step self-assembled lipid polymer hybrid nanoparticles for effective delivery of methotrexate [J].
Garg, Neeraj K. ;
Singh, Bhupinder ;
Sharma, Gajanand ;
Kushwah, Varun ;
Tyagi, Rajeev K. ;
Jain, Sanyog ;
Katare, Om Prakash .
RSC ADVANCES, 2015, 5 (77) :62989-62999